tm logo
PAPA & BARKLEY
Dead/Abandoned
ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE

failure to respond or late response

on 18 Oct 2022

Last Applicant/ Owned by

350 N GLENDALE AVE STE B123

Glendale

CA

91206

Serial Number

88977775 filed on 25th Feb 2019

Registration Number

N/A

Correspondent Address

Thomas F. Zuber

ZUBER LAWLER LLP

350 S. GRAND AVE., 32ND FLOOR

LOS ANGELES, CA 90071

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

PAPA & BARKLEY

The color(s) blue is/are claimed as a feature of the mark. PAPA AND BARKLEY Mentholated ointment for medical use, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Medicated skin oils, all of the foregoing contaiRead More

Classification Information


Class [005]
Pharmaceutical Products


Mentholated ointment for medical use, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Medicated skin oils, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Topical analgesics, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Analgesic balm, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Medicated skin creams and lotions, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; medicated skin care preparations, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; medicated herbal topical creams, gels, skin sprays, balms, liniment and ointments, all the foregoing for the relief of pain, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Topical gel for medical and therapeutic treatment of minor aches and pains of muscles and joints, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Herbal tinctures for medical purposes, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Orally-ingestible herbal tinctures for medicinal purposes in the nature of nutritional and dietary supplements, all of the foregoing containing only naturally-occurring levels of CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Medicated oral spray for pain, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Pharmaceutical, medicinal, medicated herbal, medicated botanical, and medicated preparations in the form of salves, concentrates, pastes, extracts, tinctures, and mucous membrane doses, for use in connection with pain, muscle tension, muscle spasms, and gastrointestinal illness, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Specialized tablets, capsules and powders for the delivery of pharmaceuticals sold without the pharmaceutical ingredient, all of the foregoing containing no cannabis and no cannabinoids, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Muscle soaks, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act

Mark Details


Serial Number

No 88977775

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 2869-1022

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Design Code(s)

05.07.02 -

Clusters and sheaves of other grains, including stalks of grains

24.17.14 -

Punctuation marks, including commas(,), question marks(?), exclamation points(!¡), ampersands(&), at symbols(@), and hyphens(-)

26.01.02 -

Plain single line circles

Description of Design Search

The mark consists of the stylized wording "PAPA & BARKLEY" in blue. In between the stacked words "PAPA" and "BARKLEY" is the ampersand sitting inside a blue outline of a circle with a narrow blue leaf running through the ampersand. The white in the drawing is for background areas only and is not a feature of the mark.

Legal History


Show more

Status DateAction Taken
18th Oct 2022ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
18th Oct 2022ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
26th Mar 2022SUBSEQUENT FINAL REFUSAL WRITTEN
26th Mar 2022SUBSEQUENT FINAL EMAILED
26th Mar 2022NOTIFICATION OF SUBSEQUENT FINAL EMAILED
29th Sep 2021DIVISIONAL PROCESSING COMPLETE
24th Sep 2021TEAS REQUEST TO DIVIDE RECEIVED
24th Sep 2021DIVISIONAL REQUEST RECEIVED
05th Jun 2021TEAS/EMAIL CORRESPONDENCE ENTERED
04th Jun 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED